Soticlestat in Lennox-Gastaut Syndrome (China, Phase 3)

Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Soticlestat + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Percent change from baseline in frequency of major motor drop (MMD) seizures per 28 days over the entire treatment period. Started Oct 2021; status: completed.